Please assess the completion status of the following clinical trial:

Trial Title: CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of NMIBC based on cystoscopic appearance~* ECOG 0-2~* No intravesical therapy within 6 weeks of study entry~* No prior radiation to the pelvis~* ANC \>1500/mm³; Hb \>9.0 g/dL; Platelet \>100000/mm³~* Serum creatinine ≤ 1.5 mg/dL~* Bilirubin within normal limits; AST ≤ 2.5x upper limit of normal (ULN); ALT ≤ 2.5 x ULN; alkaline phosphatase ≤ 2.5x ULN unless bone metastasis is present in the absence of liver metastasis~* INR \< 1.2; aPPT = 0.8-1.2; PT = 0.9-1.8~* Candidate for TUR and planning to undergo TUR~* Negative pregnancy test within 7 days of treatment start~* Patients of child-bearing potential must agree to use an effective method of birth control~Exclusion Criteria:~* Prior local or systemic treatments for NMIBC~* Concurrent treatment with any chemotherapeutic agent~* Patients not deemed acceptable for general anaesthesia~* Women who are pregnant or lactating~* History of vesicoureteric reflux or an indwelling urinary stent~* Administration of an investigational agent within 3 months of study entry~* Active cardiac disease~* Known infection with HIV, hepatitis B or C~* Active uncontrolled infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CVA21 (Type: EXPERIMENTAL): CVA21 was administered by intravesical instillation at one of three (3) ascending dose levels or schedules.
- CVA21/Mitomycin C (Type: EXPERIMENTAL): Mitomycin C (MMC) was administered at 10 mg by intravesical instillation on Day 1. Four hours after instillation of MMC, CVA21 was administered by intravesical instillation of one of 2 ascending dose levels or schedules. Subjects received a second instillation of CVA21 alone on Day 2 without pretreatment with MMC.

Based on this trial design, predict the completion outcome and termination type (if applicable).